These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35023647)

  • 1. Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases.
    Özlü C; Türkuçar S; Asrak HK; Dündar HA; Ünsal ŞE; Belet N
    Turk J Pediatr; 2021; 63(6):978-985. PubMed ID: 35023647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of tuberculin skin test for isoniazid prophylaxis in BCG vaccinated children who are using anti-TNF agents for rheumatologic diseases.
    Kilinc AA; Onal P; Oztosun B; Yildiz M; Adrovic A; Sahin S; Barut K; Cokugras H; Kasapcopur O
    Pediatr Pulmonol; 2020 Oct; 55(10):2689-2696. PubMed ID: 32776324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.
    Seyhoglu E; Uyaroğlu OA; Erden A; Kilic L; Karadag O; Akdogan A; Bilgen SA; Ertenli I; Kiraz S; Kalyoncu U
    Clin Rheumatol; 2021 May; 40(5):2027-2035. PubMed ID: 33057917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.
    Cuomo G; D’Abrosca V; Iacono D; Pantano I
    Clin Rheumatol; 2017 Feb; 36(2):457-461. PubMed ID: 27817127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
    Kaptan Y; Suner A; Taş MN; Oksel F; Aksu K; Sayiner A
    Clin Rheumatol; 2021 Sep; 40(9):3783-3788. PubMed ID: 33745083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between biologic modifying agents and development of latent tuberculosis in pediatrics.
    Bedir Demirdag T; Ozkaya Parlakay A; Aydin F; Tugcu GD; Santaflıoglu B; Kanik Yuksek S; Gulhan B; Cinel G; Celikel Acar B
    J Infect Dev Ctries; 2024 Jan; 18(1):116-121. PubMed ID: 38377098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of latent and active tuberculosis in BGC vaccinated, immunosuppressed Crohn's disease patients form Bulgaria before and during anti-tumor necrosis factor therapy.
    Georgieva A; Atanassova A; Mirchev M
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2399-2407. PubMed ID: 35442494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
    Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
    Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
    Taxonera C; Ponferrada Á; Riestra S; Bermejo F; Saro C; Martín-Arranz MD; Cabriada JL; Barreiro-de Acosta M; de Castro ML; López-Serrano P; Barrio J; Suarez C; Iglesias E; Argüelles-Arias F; Ferrer I; Marín-Jiménez I; Hernández-Camba A; Bastida G; Van Domselaar M; Martínez-Montiel P; Olivares D; Rivero M; Fernandez-Salazar L; Nantes Ó; Merino O; Alba C; Gisbert JP;
    J Crohns Colitis; 2018 Nov; 12(11):1270-1279. PubMed ID: 30052856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
    Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
    Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.